Company: PFSA
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112723
Chunk: 172

Company: Profusa, Inc.
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 8
Chunk 172
---

From time to time, the Company may have certain contingent liabilities
that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that
future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine
both probability and the estimated amount.

In the normal course of business, the Company enters into contracts
and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure
under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet
been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.
However, the Company may record charges in the future as a result of these indemnification obligations.

27

Note 8 — Warrants

The Company has four groups of warrants that total 17,536,750 which
is made up of: 9,487,500 Public Warrants, 7,347,500 Private Placement Warrants, 569,250 Representative’s Warrants, and 132,500 HCW
Warrants.

Northview Warrants

As part of the IPO, Northview issued the Public Warrants to third-party
investors, where each whole warrant entitled the holder to purchase one share of the Company’s Common Stock at an exercise price
of $11.50 per share. Simultaneously with the closing of the IPO, Northview completed the private sale of 7,347,500 Private Placement warrants
where each warrant allows the holder to purchase one share of the Company’s Common Stock at $11.50 per share.  Additionally,
Northview granted underwriters 569,250 warrants exercisable at $11.50 per share (or an aggregate exercise price of $6,546,375) at
the closing of the IPO.  

The Public Warrants became exercisable 30 days after the consummation
of the Business Combination

The Private Placement Warrants and Representative’s Warrants
are non-redeemable in certain circumstances so long as they are held by the initial purchasers or their permitted transferees. The Private
Placement and Representative’s Warrants may also be exercised by the initial purchasers or their permitted transferees for cash
or on a cashless basis, but are otherwise similar to the Public Warrants underlying the Units sold in the IPO, as the Private